James Loerop - 01 Feb 2025 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role: Chief Business Officer
Signature: /s/ Matthew Rothman, Attorney-in-Fact
Issuer symbol: ACRS
Transactions as of: 01 Feb 2025
Net transactions value: -$38,309
Form type: 4
Filing time: 04 Feb 2025, 16:15:08 UTC
Previous filing: 03 Jan 2025
Next filing: 05 Jan 2026
SEC: View on sec.gov

This filing has been restated, see here for the amended filing

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ACRS	Common Stock	Options Exercise		+11,250	+13%		96,503	01 Feb 2025	Direct	F1
transaction	ACRS	Common Stock	Options Exercise		+7,500	+7.8%		104,003	01 Feb 2025	Direct	F1
transaction	ACRS	Common Stock	Options Exercise		+14,750	+14%		118,753	01 Feb 2025	Direct	F1
transaction	ACRS	Common Stock	Tax liability	$38,309	-15,447	-13%	$2.48	103,306	01 Feb 2025	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ACRS	Restricted Stock Units	Options Exercise	$0	-11,250	-50%	$0.000000	11,250	01 Feb 2025	Common Stock	11,250		Direct	F1, F3
transaction	ACRS	Resticted Stock Units	Options Exercise	$0	-7,500	-33%	$0.000000	15,000	01 Feb 2025	Common Stock	7,500		Direct	F1, F4
transaction	ACRS	Restricted Stock Units	Options Exercise	$0	-14,750	-25%	$0.000000	44,250	01 Feb 2025	Common Stock	14,750		Direct	F1, F5
transaction	ACRS	Restricted Stock Units	Award	$0	+83,500		$0.000000	83,500	03 Feb 2025	Common Stock	83,500		Direct	F1, F6
transaction	ACRS	Employee Stock Option (Right to Buy)	Award	$0	+292,300		$0.000000	292,300	03 Feb 2025	Common Stock	292,300	$2.40	Direct	F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F2	The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4.
F3	The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2022, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.
F4	The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2023, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.
F5	The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.
F6	The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.
F7	Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.